Physician profile
Daniel T Layish
NPI 1659350320
$61,887.39
in general payments reported to CMS, 2019-2025
59 companies · $5,526 in 2025
The $5,526 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $16K · 2021: $6,009 · 2022: $2,203 · 2023: $1,356 · 2024: $1,724 · 2025: $5,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,340 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,450 · Education: $615 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,340.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,450.00 |
| Education | $615.34 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14,278.95 | 2019-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $7,249.35 | 2019-2024 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $7,139.80 | 2019-2024 | |
| Mylan Specialty L.P. | $5,019.53 | 2019-2023 | Yupelri |
| Viiv Healthcare Company | $4,240.09 | 2019 | |
| Genentech USA, INC. | $4,027.83 | 2019-2023 | Xolair |
| Jazz Pharmaceuticals INC. | $3,567.11 | 2019-2025 | |
| Lilly USA, LLC | $3,468.43 | 2025 | Zepbound |
| Philips North America LLC | $2,104.36 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Actelion Pharmaceuticals US, INC. | $1,541.54 | 2019-2025 | Uptravi, Opsumit |
| Genentech, INC. | $1,173.10 | 2019-2022 | |
| Allergan, INC. | $1,016.06 | 2019-2021 | |
| Insmed, INC. | $823.14 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.60 | 2019-2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $625.19 | 2020-2025 | Wakix |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $480.54 | 2019-2023 | Veklury |
| Chiesi USA, INC. | $426.51 | 2020-2023 | Bronchitol |
| United Therapeutics Corporation | $338.42 | 2019-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $336.37 | 2019-2025 | |
| Abbvie INC. | $299.57 | 2020-2025 | |
| Vertex Pharmaceuticals Incorporated | $273.08 | 2020-2025 | Trikafta |
| Avadel Cns Pharmaceuticals, LLC | $265.79 | 2024-2025 | Lumryz |
| Nestle Healthcare Nutrition INC. | $227.98 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $219.13 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Viatris Specialty LLC | $170.65 | 2025 | Tobi Podhaler, Yupelri |
| Medtronic, INC. | $157.11 | 2024 | Hawkone |
| Merck Sharp & Dohme LLC | $142.42 | 2023-2025 | Winrevair |
| Inari Medical, INC. | $137.73 | 2022 | |
| Alcresta Therapeutics, INC. | $133.30 | 2019-2025 | Relizorb |
| Electromed, INC. | $132.16 | 2019-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $127.12 | 2019-2025 | |
| Vifor Pharma, INC. | $124.00 | 2024-2025 | Zemaira |
| Regeneron Healthcare Solutions, INC. | $105.62 | 2019-2023 | Dupixent |
| Medtronic Vascular, INC. | $81.28 | 2019 | |
| Aimmune Therapeutics, INC. | $81.19 | 2024-2025 | Zenpep |
| Advanced Respiratory, INC | $78.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.68 | 2021-2024 | Glassia |
| Breathe Technologies, INC. | $70.42 | 2019 | |
| Vapotherm INC | $47.98 | 2019-2023 | Vapotherm |
| Portola Pharmaceuticals, LLC | $45.28 | 2019 | |
| Paratek Pharmaceuticals, INC. | $44.96 | 2022-2023 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $37.02 | 2019 | |
| Csl Behring | $34.64 | 2020-2024 | Kcentra |
| Resmed Corp | $32.63 | 2024-2025 | |
| Digestive Care, INC. | $28.15 | 2024 | Pertzye |
| Pfizer INC. | $25.08 | 2019 | |
| Vivus LLC | $22.10 | 2025 | Pancreaze |
| Itamar Medical INC | $20.08 | 2025 | Watchpatone |
| Breas Medical, INC. | $14.95 | 2023 | Vivo 45 Ls |
| Nabriva Therapeutics, Plc | $13.86 | 2020 | |
| Baxter Healthcare | $13.58 | 2024 | Hillrom - Monarch Airway Clearance System |
| Sandoz INC. | $13.24 | 2019 | |
| Phadia US INC. | $11.26 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Layish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.